Logo.jpg
LIXTE Biotechnology Holdings announces collaboration on a New Colon Cancer Clinical Trial
14 juin 2024 11h00 HE | Lixte Biotechnology Holdings, Inc.
Clinical trial to test recent findings that show LIXTE’s lead clinical compound, LB-100, increases recognition of colon cancer cells by the immune system PASADENA, CA, June 14, 2024 (GLOBE...
Algernon Logo 1.png
Algernon Pharmaceuticals Announces Receipt of Refundable Tax Credit from Australian Clinical Research
16 nov. 2020 08h00 HE | Algernon Pharmaceuticals
VANCOUVER, British Columbia, Nov. 16, 2020 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”), a clinical stage pharmaceutical...
Algernon Logo 1.png
Algernon Pharmaceuticals Announces Plans to Provide Interim Data from its Ifenprodil Phase 2b/3 COVID-19 Human Study
09 nov. 2020 08h00 HE | Algernon Pharmaceuticals
VANCOUVER, British Columbia, Nov. 09, 2020 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmaceutical...
Algernon Logo 1.png
Algernon Pharmaceuticals Appoints Novotech as CRO for First Phase 2 Trial and Announces Novotech’s $220K Equity Investment
17 janv. 2020 06h00 HE | Algernon Pharmaceuticals
VANCOUVER, British Columbia, Jan. 17, 2020 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”), a clinical stage pharmaceutical...
Algernon Logo 1.png
Algernon Pharmaceuticals Provides Update on its Planned Phase II Clinical Trial
25 nov. 2019 07h00 HE | Algernon Pharmaceuticals
VANCOUVER, B.C., Nov. 25, 2019 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCB: BTHCF) (the “Company” or “Algernon”), a clinical stage pharmaceutical development...
Algernon Logo 1.png
Algernon Pharmaceuticals Announces Short Form Prospectus Unit Offering
04 juil. 2019 07h00 HE | Algernon Pharmaceuticals
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION, DISTRIBUTION OR DISSEMINATION DIRECTLY, OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES VANCOUVER, British...
Algernon Logo 1.png
Algernon Pharmaceuticals’ NP-120 Reduced Fibrosis in an Idiopathic Pulmonary Fibrosis Study by 56% Outperforming USFDA Approved Treatments Nintedanib and Pirfenidone
03 juil. 2019 07h00 HE | Algernon Pharmaceuticals
VANCOUVER, British Columbia, July 03, 2019 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCB: BTHCF) (the “Company” or “Algernon”), a clinical stage pharmaceutical...
Algernon Logo 1.png
Algernon Pharmaceuticals Appoints Leading Inflammatory Bowel Disease Expert Dr. Walter Reinisch to Its Medical and Scientific Advisory Board
04 avr. 2019 07h00 HE | Algernon Pharmaceuticals
VANCOUVER, British Columbia, April 04, 2019 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCB: BTHCF) (the “Company” or “Algernon”) a clinical stage pharmaceutical...
Algernon Logo 1.png
Algernon Pharmaceuticals Begins Trading on The CSE Under The Symbol AGN
19 févr. 2019 07h00 HE | Algernon Pharmaceuticals
VANCOUVER, British Columbia, Feb. 19, 2019 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) a clinical stage pharmaceutical development company is pleased to announce...